Yahoo
HKSE - Delayed Quote HKD

Guangzhou Innogen Pharmaceutical Group Co., Ltd (2591.HK)

3.400 +0.130 (+3.98%)
At close: October 30 at 4:08:06 PM GMT+8
Chart Range Bar
Loading chart for 2591.HK
  • Previous Close 3.270
  • Open 3.295
  • Bid 3.400 x --
  • Ask 3.405 x --
  • Day's Range 3.275 - 3.695
  • 52 Week Range 3.130 - 48.360
  • Volume 51,029,400
  • Avg. Volume 8,694,586
  • Market Cap (intraday) 1.553B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.910
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 20.71

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.

www.innogenpharm.com

214

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2591.HK
88.84%
HANG SENG INDEX (^HSI)
9.11%

1-Year Return

2591.HK
88.59%
HANG SENG INDEX (^HSI)
11.37%

3-Year Return

2591.HK
95.28%
HANG SENG INDEX (^HSI)
33.83%

5-Year Return

2591.HK
95.28%
HANG SENG INDEX (^HSI)
8.21%

Analyst Insights

View More

Analyst Price Targets

12.63
20.71 Average
3.400 Current
28.79 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -218.13%

  • Return on Assets (ttm)

    -19.04%

  • Return on Equity (ttm)

    -41.16%

  • Revenue (ttm)

    153.28M

  • Net Income Avi to Common (ttm)

    -334.35M

  • Diluted EPS (ttm)

    -0.910

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.02B

  • Total Debt/Equity (mrq)

    16.05%

  • Levered Free Cash Flow (ttm)

    -266.05M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: